Trevi Therapeutics Inc. (TRVI)
NASDAQ: TRVI
· Real-Time Price · USD
7.51
0.02 (0.27%)
At close: Aug 15, 2025, 3:59 PM
7.52
0.07%
After-hours: Aug 15, 2025, 04:10 PM EDT
Trevi Therapeutics Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -12.3M | -10.34M | -11.41M | -13.24M | -12.35M | -10.9M | -7.82M | -7.7M | -7.14M | -6.4M | -5.5M | -8.27M | -8.05M | -7.33M | -8.52M | -7.25M | -9.79M | -8.37M |
Depreciation & Amortization | 38K | 37K | 38K | 36K | 38K | 35K | 35K | 35K | 34K | 19K | 15K | 9K | 8K | 11K | 12K | 13K | 12K | 13K |
Stock-Based Compensation | 1.38M | 1.21M | 917K | 821K | 1.13M | 723K | 534K | 530K | 605K | 578K | 501K | 569K | 520K | 737K | 540K | 540K | 745K | 718K |
Other Working Capital | -503K | -2.11M | -790K | 3.02M | 3.35M | -356K | 109K | 377K | -2.38M | 914K | -1.42M | 654K | -910K | 434K | 1.02M | 560K | -2.03M | 1.13M |
Other Non-Cash Items | -273K | -283K | -99K | 5.49M | -223K | -261K | 134K | 119K | 239K | -580K | -460K | -74K | 207K | 165K | 157K | 151K | 521K | 145K |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a | 23K | -472K | -631K | n/a | n/a | n/a | n/a | n/a | -53K | 5K | -40K | 6K |
Change in Working Capital | 1.05M | -4.1M | 1.01M | -2.67M | 2.73M | -62K | 736K | 207K | -2.98M | -1.81M | -882K | -814K | 1.14M | -676K | 1.64M | -695K | 658K | -89K |
Operating Cash Flow | -10.1M | -13.48M | -9.55M | -9.56M | -8.68M | -10.47M | -6.36M | -7.28M | -9.88M | -8.2M | -6.33M | -8.58M | -6.18M | -7.09M | -6.23M | -7.24M | -7.9M | -7.58M |
Capital Expenditures | n/a | 13.48M | -7K | n/a | -28K | n/a | -22K | -18K | -40K | -57K | -116K | -43K | n/a | n/a | n/a | n/a | n/a | n/a |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -671K | 1.2M | -1.96M | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | -17.11M | -27.55M | -45.19M | -13.05M | -9.96M | -30.26M | -951K | n/a | n/a | -8.98M | -65.19M | -6.81M | -54.22M | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | 14.12M | 17.59M | 21.33M | 19.65M | 12.75M | 22.17M | 13.82M | 18M | 19.68M | 18M | 17M | 2M | -72K | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | 383K | n/a | n/a | 1.07M | n/a | n/a | n/a | n/a | 19.68K | 671K | -1.2M | 1.96M | 72K | n/a | n/a | n/a | n/a | n/a |
Investing Cash Flow | -2.61M | -9.95M | -23.87M | 7.67M | 2.77M | -8.09M | 12.85M | 17.98M | 19.64M | 8.96M | -48.31M | -4.85M | -54.22M | n/a | n/a | n/a | n/a | n/a |
Debt Repayment | n/a | -11K | -31K | -32K | -31K | -32K | -32K | -31K | -7.69M | -1.75M | -1.75M | -1.75M | -1.75M | -583K | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | n/a | n/a | 49K | 163K | 4.85M | n/a | 1.71M | n/a | 28K | 47K | 2K | 5.87M | 5.9M | -42K | 63K | -399K | -41K | -31K |
Financial Cash Flow | 110.39M | 8.71M | 51.47M | 4.98M | 5.07M | -28K | -54K | 1.51M | -7.66K | -1.7K | 652K | 55.3M | 55.98M | -625K | 13.74M | 134K | 2.75M | 4.15M |
Net Cash Flow | 97.68M | -14.72M | 18.05M | 3.09M | -848K | -18.59M | 6.43M | 12.21M | 2.1M | -938K | -53.98M | 41.88M | -4.42M | -7.72M | 7.51M | -7.11M | -5.14M | -3.43M |
Free Cash Flow | -10.1M | -13.48M | -9.56M | -9.56M | -8.71M | -10.47M | -6.38M | -7.3M | -9.91M | -8.25M | -6.45M | -8.62M | -6.18M | -7.09M | -6.23M | -7.24M | -7.9M | -7.58M |